SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 8-K - Current report:
SEC Accession No. 0001193125-24-158318
Filing Date
2024-06-10
Accepted
2024-06-10 16:05:30
Documents
13
Period of Report
2024-06-07
Items
Item 5.07: Submission of Matters to a Vote of Security Holders

Document Format Files

Seq Description Document Type Size
1 8-K d850029d8k.htm   iXBRL 8-K 36605
  Complete submission text file 0001193125-24-158318.txt   163016

Data Files

Seq Description Document Type Size
2 XBRL TAXONOMY EXTENSION SCHEMA ikt-20240607.xsd EX-101.SCH 2857
3 XBRL TAXONOMY EXTENSION LABEL LINKBASE ikt-20240607_lab.xml EX-101.LAB 18738
4 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE ikt-20240607_pre.xml EX-101.PRE 11713
16 EXTRACTED XBRL INSTANCE DOCUMENT d850029d8k_htm.xml XML 3768
Mailing Address 3350 RIVERWOOD PARKWAY SE, SUITE 1900 ATLANTA GA 30339
Business Address 3350 RIVERWOOD PARKWAY SE, SUITE 1900 ATLANTA GA 30339 678-392-3419
Inhibikase Therapeutics, Inc. (Filer) CIK: 0001750149 (see all company filings)

IRS No.: 263407249 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-39676 | Film No.: 241032679
SIC: 2836 Biological Products, (No Diagnostic Substances)
(CF Office: 03 Life Sciences)